secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-07-31T12:48:17+00:00
Accession:  0001628280-26-051251
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen appoints Douglas J. Williamson, M.D. to Board of Directors
-------------------------------------------------------------------

- Dr. Williamson appointed to Vistagen's Board effective July 29, 2026.
- He received options to purchase 40,826 shares at $0.2433, vesting over three years.
- Williamson brings 30 years of neuroscience drug development and regulatory experience.
- He previously served as CMO of QurAlis, EVP R&D at Acadia, and senior roles at Lundbeck and Eli Lilly.
- He will serve until the next annual meeting or until successor is elected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026051251/0001628280-26-051251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026051251/vtgn-20260729.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-051251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer